Dr. Victoria Whitmore

I've had patients come to me after neuropathy surgery who were worse than when they went in. Not slightly worse. Noticeably, measurably, undeniably worse. And for a long time, I didn't have an honest answer for why. I trained for over a decade to perform nerve decompression surgeries. Tarsal tunnel release. Peroneal nerve release. Lumbar nerve root decompression. These are real procedures. I'm good at them. And in the right patient, under the right conditions, they matter. But something nobody told me in my training — and nobody told those patients before they went under — is that surgery cannot fix what surgery didn't break. And in peripheral neuropathy, surgery almost never addresses the thing that's actually broken. I want to explain what I mean. Because I think it might be the most important thing a neuropathy patient can hear before making any decision about their care. Let me start with Margaret. She was a sixty-one-year-old school librarian. Twenty-eight years of sitting at a reference desk, helping students, quiet work that didn't look stressful from the outside. But her feet told a different story. By the time she found my office, she'd been living with burning, stabbing pain in both feet for three years. Nighttime was the worst — she'd described lying in bed with her feet on fire, unable to sleep more than two hours at a stretch. Her previous neurologist had ordered an EMG and nerve conduction study. The results showed reduced signal velocity in the peroneal and sural nerves. The recommendation was surgical decompression — release the fibrous tissue compressing the nerve at four points in each leg. Margaret asked me if she should do it. I told her yes. And I still think about that conversation. She had the surgery. Both legs. Bilateral decompression. It was technically clean. No complications. The tissue was released exactly as planned. Ten weeks post-op, she came back for her follow-up. "It's worse," she said. She didn't say it dramatically. She said it the way someone says something when they've already accepted a terrible thing. Quietly. Like a door closing. The burning had spread from her feet to her ankles. Her fingertips had started tingling. She was dropping her keys. I ordered new nerve conduction studies. The compression was gone. I could see that. But the nerve function wasn't better. In some measurements, it had declined further. The surgery had done everything it was supposed to do. And the patient was still deteriorating. That's when I spent the first of many nights unable to sleep, turning the same question over and over: If the compression was the problem, and we removed the compression, why is she getting worse? I started pulling research. Not clinical guidelines — actual bench science. Neuroscience papers. Cellular biology journals. And I found something that should be taught in every medical school that trains surgeons who operate on nerves. It came from a research group at the University of Copenhagen. They had been studying why peripheral nerve regeneration so frequently stalls — even in cases where the structural cause of compression had been successfully addressed. Their conclusion: *"Mitochondrial dysfunction within the Schwann cells and axons of damaged peripheral nerves creates an energetic deficit that prevents remyelination, regardless of whether external compression has been relieved."* I read that sentence and felt the floor shift under me. Myelination — the rebuilding of the protective sheath around nerve fibers — is a metabolically expensive process. It requires enormous quantities of cellular energy. ATP. Produced by mitochondria inside the nerve cells and the support cells that wrap them. And years of neuropathy — the inflammation, the oxidative stress, the poor circulation — quietly destroys that mitochondrial function long before a surgeon ever makes an incision. So when the patient goes in for decompression, the nerve is already energetically bankrupt. The compression is real. The surgery addresses the compression. But the nerve cells are still running on empty. They don't have the biological resources to begin repairs. The structural problem was fixed. The energetic problem was never identified. Never addressed. Never even discussed. Think of a construction crew sent to rebuild a collapsed bridge. You remove the rubble. You clear the site. But if you send a crew with no tools, no materials, no fuel — nothing gets built. That's what we were doing. We cleared the rubble. We sent in an empty crew. And then we told patients to give it time. Once I understood this, I couldn't operate the same way anymore. I started asking: before we discuss surgery, what can we do to restore the metabolic environment inside these nerve cells? Because if we go in surgically without addressing the energy deficit, we may relieve compression while the nerves remain biologically incapable of healing. That question led me, after months of research, to something I had never encountered in my surgical training. A colleague who specialized in integrative neurology — someone who had spent fifteen years working with post-surgical neuropathy patients who hadn't improved — described a compound he'd been incorporating into his protocols. He said, "I know how it sounds. But the mechanism is real. Look at the electron transport chain literature." He was talking about Methylene Blue. Not a drug in the traditional sense. A compound that has been studied in biomedical science for over a hundred years, increasingly recognized for one specific property that is directly relevant to neuropathy: it acts as an alternative electron carrier in the mitochondrial transport chain. In plain language, it bypasses the damaged steps in a nerve cell's energy production process — and helps the cell generate ATP through a different pathway, even when the normal machinery is compromised. That's not a metaphor. That's the documented biochemistry. He walked me through the three things it does that nothing else addresses together: **It restores mitochondrial energy production in nerve cells.** Not by stimulating the damaged system, but by carrying electrons through an alternative route. Giving the nerve cell fuel it can actually use. **It neutralizes free radical damage in nerve tissue.** The oxidative stress that has been burning through nerve fibers for years — attacking myelin, disrupting signaling, killing Schwann cells — gets interrupted at the molecular level. **It supports the biological conditions needed for remyelination.** When the energy crisis is relieved and the oxidative environment is calmed, the cells responsible for rebuilding myelin can finally do their job. He said, "The reason your post-surgical patients don't improve is that you successfully removed the compression, but the nerve cells still can't produce enough energy to rebuild. This gives them that energy." I spent six weeks going through every paper I could find. The mechanistic data was solid. The results in early clinical work were consistent: improved nerve conduction velocity, reduced pain scores, measurable improvement in nerve regeneration markers. It was addressing the problem underneath the problem. But availability was an issue. Most Methylene Blue formulations were pharmaceutical solutions designed for IV use or specific clinical applications — not accessible, not appropriate for daily neuropathy support, and not formulated for consistent bioavailability. Until my colleague showed me what Boovelle had built. A team that included neuroscience researchers and formulators who had dealt with neuropathy personally — not just professionally — had spent years developing a form that could deliver Methylene Blue in a reliable, daily-use gummy format with the consistency and bioavailability that the clinical research required. Boovelle™ Methylene Blue Gummies. Not another supplement with a long ingredient label and vague claims. A targeted formulation designed specifically around the mitochondrial mechanism in peripheral nerve cells. I tried them myself. Years of surgical work had left me with intermittent hand tingling that I'd normalized as occupational reality. Within three weeks, the tingling was measurably reduced. By week six, I had forgotten it had been there. Then I started recommending them — carefully, selectively — to post-surgical neuropathy patients who hadn't responded the way the textbooks said they should. Margaret was one of the first. She came back after eight weeks. "The burning is quieter," she said. Still quietly. But this time it wasn't a door closing. It was something opening. By the four-month mark, she was sleeping through the night. A retired firefighter I'd operated on two years prior — bilateral tarsal tunnel, minimal post-surgical improvement — told me he'd started cooking again. His hands had been too unreliable to hold a knife safely. Now he was making Sunday dinners for his grandchildren. I am not telling you surgery is never the answer. I am telling you that surgery without addressing the cellular energy environment of the nerve is, in many cases, an incomplete answer. And for some patients, it makes things worse — not because the surgeon failed, but because the underlying mechanism was never the compression alone. Before you go into an operating room for a neuropathy procedure, please ask: what is being done to support mitochondrial function in my nerve cells? What is being done to address the oxidative damage that years of neuropathy has caused inside those nerve fibers? If nobody has asked that question, you haven't had the full conversation. Right now, Boovelle is offering 40% off, backed by a full 60-day money-back guarantee. No risk. No commitment beyond two months. Just the chance to find out whether addressing the root biological mechanism makes a difference for you — before, or instead of, anything more invasive. https://boovelle.com/products/boovelle%E2%84%A2-methylene-blue-gummies I've stood at an operating table and done everything right — and watched patients walk out still suffering. I'm not willing to keep doing that without offering them this piece of the puzzle first. Because sometimes the nerve doesn't need a scalpel. It needs a reason to believe it can repair itself. And that reason starts at the cellular level.